Literature DB >> 19126958

In vivo imaging of cancer biomarkers using activatable molecular probes.

Drew R Elias1, Daniel L J Thorek, Antony K Chen, Julie Czupryna, Andrew Tsourkas.   

Abstract

With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as "activatable molecular probes" has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19126958     DOI: 10.3233/cbm-2008-4602

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  25 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

Review 2.  Molecular body imaging: MR imaging, CT, and US. part I. principles.

Authors:  Moritz F Kircher; Jürgen K Willmann
Journal:  Radiology       Date:  2012-06       Impact factor: 11.105

Review 3.  MRI biosensors: a short primer.

Authors:  Angelique Louie
Journal:  J Magn Reson Imaging       Date:  2013-09       Impact factor: 4.813

Review 4.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 5.  The evolution of imaging in cancer: current state and future challenges.

Authors:  Luke J Higgins; Martin G Pomper
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

6.  Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.

Authors:  Santimukul Santra; Charalambos Kaittanis; Oscar J Santiesteban; J Manuel Perez
Journal:  J Am Chem Soc       Date:  2011-09-27       Impact factor: 15.419

Review 7.  Optical and x-ray technology synergies enabling diagnostic and therapeutic applications in medicine.

Authors:  Brian W Pogue; Brian C Wilson
Journal:  J Biomed Opt       Date:  2018-10       Impact factor: 3.170

Review 8.  Molecular magnetic resonance contrast agents for the detection of cancer: past and present.

Authors:  Alexei Bogdanov; Mary L Mazzanti
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

9.  Diamagnetic Imaging Agents with a Modular Chemical Design for Quantitative Detection of β-Galactosidase and β-Glucuronidase Activities with CatalyCEST MRI.

Authors:  Gabriela Fernández-Cuervo; Kirsten A Tucker; Scott W Malm; Kyle M Jones; Mark D Pagel
Journal:  Bioconjug Chem       Date:  2016-10-06       Impact factor: 4.774

10.  Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model.

Authors:  Greg M Thurber; Jose L Figueiredo; Ralph Weissleder
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.